论文部分内容阅读
据中国医学论坛报报道,研究共纳入3876例过去6个月内发生过缺血性卒中或短暂性脑缺血发作(TIA)的患者,随机分为吡格列酮组或对照组,用药时间为5年。主要终点事件为随访期内发生的卒中或心肌梗死。结果显示,与对照组相比,吡格列酮组和对照组发生卒中或心肌梗死的比例分别为9.0%和11.8%(P=0.007),服用吡格列酮使绝对风险下降2.9%,相对风险下降24%。另外,服用吡格列酮可使糖尿病发生率下降52%(P=0.007)。但是,在副作
According to the China Medical Tribune, 3876 patients with ischemic stroke or transient ischemic attack (TIA) in the past 6 months were enrolled and randomized to pioglitazone or control group for a period of 5 years . The primary endpoint was stroke or myocardial infarction during follow-up. The results showed that compared with the control group, the rates of stroke or myocardial infarction in the pioglitazone group and the control group were 9.0% and 11.8%, respectively (P = 0.007). Pioglitazone decreased the absolute risk by 2.9% and the relative risk by 24%. In addition, pioglitazone reduced the incidence of diabetes by 52% (P = 0.007). However, in the deputy